TB-500 vs Thymosin Alpha-1: Literature and Handling Compared
Researchers comparing TB-500 and Thymosin Alpha-1 are usually resolving one question: which compound the published record actually supports for the model in front of them.
Compound profiles
TB-500 in the indexed record
The literature on TB-500 is a limited body of work: 26 PubMed-indexed records, alongside 1 registered studies on ClinicalTrials.gov.
Journals represented in the current index include Am J Sports Med, Front Aging, J Am Acad Orthop Surg Glob Res Rev, spanning 2024–2026.
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — J Am Acad Orthop Surg Glob Res Rev, 2026. PMID: 41490200
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians — Am J Sports Med, 2026. PMID: 41476424
- Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro — J Chromatogr B Analyt Technol Biomed Life Sci, 2024. PMID: 38382158
- Peptide Supplements and Their Therapeutic Applications in Sports Medicine — Am J Sports Med, 2026. PMID: 42578445
Thymosin Alpha-1 in the indexed record
Searching Thymosin Alpha-1 against the PubMed index returns 582 records, a substantial evidence base, alongside 66 registered studies on ClinicalTrials.gov.
Recent indexed work appears in Am J Health Syst Pharm, Expert Opin Biol Ther, Int J Mol Sci, spanning 2001–2025.
- Thymosin alpha-1 — Am J Health Syst Pharm, 2001. PMID: 11381492
- Thymosin alpha 1: A comprehensive review of the literature — World J Virol, 2020. PMID: 33362999
- Aging and Thymosin Alpha-1 — Int J Mol Sci, 2025. PMID: 41373628
- Thymosin Alpha 1 Plus Routine Treatment for the Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis — J Coll Physicians Surg Pak, 2024. PMID: 39648386
Side-by-side research profile
| Parameter | TB-500 | Thymosin Alpha-1 |
|---|---|---|
| PubMed indexed records | 26 | 582 |
| Registered studies (ClinicalTrials.gov) | 1 | 66 |
| Literature depth | Emerging | Extensive |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
Classification and why it matters
TB-500 and Thymosin Alpha-1 sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for TB-500 describes conditions validated for TB-500: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to Thymosin Alpha-1 without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
How the literature differs
The indexed record is not symmetrical between these two compounds. Thymosin Alpha-1 carries 556 more indexed records than TB-500, which means published methodology, characterisation data and replication attempts are more readily located for Thymosin Alpha-1. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (1 vs 66) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Documentation standards
Identity and purity are separate claims requiring separate methods. A purity percentage quoted without the analytical method behind it, or a certificate with no lot reference, is a documentation gap rather than verification.
Selecting between them for a study design
TB-500 and Thymosin Alpha-1 are not interchangeable. They differ in structural class and in the pathways the literature associates with each, so substituting one for the other changes what a model is actually measuring.
Where a protocol cites a specific compound, the cited compound is the one the published result applies to. Where no protocol exists, the compound with the deeper indexed record (Thymosin Alpha-1) generally offers more methodological precedent.
Storage and stability
Lyophilised peptide is the stable form. Held sealed at -20°C and shielded from light, it tolerates long storage; once reconstituted that tolerance drops sharply and the working solution is treated as short-lived.
Each freeze-thaw cycle costs integrity, which is why reconstituted material is normally split into single-use aliquots.
Frequently asked questions
Are TB-500 and Thymosin Alpha-1 the same compound?
No. They are structurally distinct research compounds with separate literature records — 26 indexed records for TB-500 and 582 for Thymosin Alpha-1.
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
Which of TB-500 or Thymosin Alpha-1 has more published research?
Thymosin Alpha-1, with 582 indexed PubMed records against 26.
How should these compounds be stored?
Lyophilised material is conventionally stored at -20°C protected from light. Reconstituted solution is far less stable and is held at 2-8°C for short-duration laboratory work only.
Related references
- TB-500 — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.